Please login to the form below

CAR therapies

This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.

Gilead strikes deal with NHS England on CAR-T Yescarta

Dr Alasdair Rankin, Director of Research and Patient Experience at Bloodwise, said: “CAR-T therapies have shown huge promise in treating patients with lymphoma who have no other chance of cure. ... the chimeric antigen receptor (CAR), and then

Latest news

Novartis cuts manufacturing jobs in Switzerland and UK

This reflects the move away from simpler small molecule-based pills towards a greater reliance on biologics and the new and highly complex manufacturing required for cell therapies, such as ... The company is currently struggling to scale up its CAR-T
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

NHS England’s commissioning expert told NICE that healthcare professionals would require “extensive training in managing and supporting patients”who had received CAR-T therapies, and that a new service specification ... NICE's Meindert Boysen.
Gilead optimistic about Yescarta deal in UK

Gilead optimistic about Yescarta deal in UK. Says NICE and NHS England understand groundbreaking nature of CAR-T. ... Approved in the US around a year ago, the CAR-T therapies work by taking a patient’s own T cells, re-engineering them to fight cancer
It’s a no for Yescarta, says NICE on heels of EU approval

CAR T cell therapy uses a patient’s own genetically modified immune cells to target their cancer. ... NHS England chief executive Simon Stevens acknowledged at the UK industry association ABPI conference earlier this year that the CAR-T therapies were
Novartis and Gilead's rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability. Novartis and Gilead/Kite have picked up EU approvals for their CAR-T therapies for blood cancers from the European Commission, but ... Novartis says the roll-out of Kymriah in Europe will

More from news
Approximately 1 fully matching, plus 39 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... molecular defects that are driving its
30 Women Leaders in UK Healthcare

Current projects include developing antibodies for use as cancer imaging agents, antibody drug conjugates, chimeric antigen receptor therapies (CAR-Ts) and nano-medicines.
The good, the bad and the ugly

The oncology market is certainly evolving. “Some of the most interesting play is in immuno-oncology, where combination therapies are increasingly being explored. ... It will also be interesting to see how gene therapies and cell-based therapies, like
Cell and gene therapies: on course for commercial success?

The data for the research was derived from published data on CAR-T pipeline therapies, but was not related to any particular product. ... The NICE appraisal methods and decision framework are applicable to regenerative medicines and cell therapies.
Deal Watch November 2016

were thought to be a result of the chemotherapy regimen used to prepare the patients before administering the CAR T cell therapy. ... their own CAR T cell therapies - so CAR T cell therapy seems to be still alive and doing well.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult, Filippo Petti joins Ceylad and Vivienne Fox to chair RFI

Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Training the next generation of biotech leaders

In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... From dream to reality. The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality,
Addressing the biggest challenges for rare disease communities

And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
Addressing the biggest challenges for rare disease communities

And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Editorial Director – Medical Education: Neg

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Director – Head of Public Affairs: Neg

Account Manager, Healthcare Advertising: Salary TBC

Senior Account Executive – Medical Communications: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Associate Medical Director: Highly Competitive

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Director Healthcare PR Communications: Salary TBC

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Experienced Editor, London, Medical Communications: Competitive package

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Team Lead: Competitive Salary

Account Director: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Scientific Director: Highly Competitive Salary &Benefits

Account Director - Digital: Great salary and benefits

Associate Medical Director: Salary TBC

Project / Account Manager (Medical Education): Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...
Tackling a formidable foe: Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies: With patient numbers set to soar, how can we make a difference?...